An interim analysis of a phase II study using an epigenetic biomarker (CHFR methylation status) to personalize chemotherapy in patients with operable esophageal cancer.
Ronan J. Kelly(Baylor University Medical Center), James G. Herman(UPMC Hillman Cancer Center), Tammy Beckman(Sidney Kimmel Comprehensive Cancer Center), Amanda Choflet(Sidney Kimmel Comprehensive Cancer Center), Jeffrey Reynolds(Sidney Kimmel Comprehensive Cancer Center), Russell K. Hales(Johns Hopkins University), John Wrangle(Johns Hopkins University), Stephen C. Yang(Johns Hopkins University), Margaret Lang(Johns Hopkins Hospital), Daniela Molena(Memorial Sloan Kettering Cancer Center), Malcolm V. Brock(Johns Hopkins University), Kristen Rodgers(Johns Hopkins University)
Cited by 2
Related Papers
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
|Cancer Discovery|2016|909